VVT Medical

Develops, manufactures, and commercializes minimally invasive, non-thermal, non-tumescent solutions for the treatment of varicose veins.

Health Tech & Life Sciences
Public on TSXV on Jul 2025
Public Kefar Sava, Israel Founded 2007
Last updated 2026-07-26
Total raised
$31.0M
Last: PIPE 2026-03
Stage
Public
Founded
2007
Headcount
21
HQ
Kefar Sava, Israel
Sector
Health Tech & Life Sciences
Website ↗LinkedIn ↗

About

VVT Medical specializes in the research, development, manufacturing, and commercialization of minimally invasive, non-thermal, non-tumescent (NT-NT) solutions for treating varicose veins. Its core product, the ScleroSafe platform, combines best practices in vein treatment with a patented delivery system, enabling physicians to perform quick, office-based procedures without the need for tumescent anesthesia or costly capital equipment. The company's solutions, including ScleroSafe with V-Block, are designed to treat severely dilated and challenging Great Saphenous Vein conditions.

Funding history · 2 rounds · $31.0M total

3 events/rounds · $31.0M Total Funding: $29.9M in Public Equity, $1.1M in Debt
Apr 2026
Debt Financing $1.1M globenewswire.com ↗
★ Michal Tisser★ other insiders★ Uber Ros S.p.A.★ eligible finders★ Insiders of the Company★ other unnamed insiders and eligible finders
Jul 2025
Follow-on PO $29.9M tsx.com ↗
★ V.V.T. Med Ltd.★ DXI Capital Corp.★ Exiteam Acquisition Corp.★ Exiteam Acquisition Corp. (EAC) subscription receipt holders

Headcount over time

21 employees (2026-09) · 1 point
21 21 2026-09

Offices

Kefar Sava, Israel · HQ / main office

Q&A

When did VVT Medical become a public company?
VVT Medical became public on the TSX Venture Exchange in July 2025.
What is VVT Medical's primary focus?
VVT Medical specializes in the research, development, manufacturing, and commercialization of minimally invasive, non-thermal, non-tumescent solutions for treating varicose veins.
What is VVT Medical's core product?
VVT Medical's core product is the ScleroSafe platform, which provides a patented delivery system for office-based procedures to treat varicose veins without tumescent anesthesia or costly capital equipment.
Which investor participated in VVT Medical's PIPE round in July 2025?
I3 Capital Group was a lead investor in VVT Medical's PIPE round in July 2025.
What was the amount raised in VVT Medical's PIPE round in March 2026?
VVT Medical raised $1,065,664 in its PIPE round in March 2026.
What is the employee count for VVT Medical?
VVT Medical has 11-50 employees.
In June 2026, how did VVT Medical expand its European commercial footprint?
In June 2026, VVT Medical expanded its European commercial footprint through an exclusive distribution agreement in Greece.
What significant distribution deal did VVT Medical sign in November 2025?
In November 2025, VVT Medical signed a $3.7 million distribution deal in India.
When did VVT Medical announce the first patients treated with its ScleroSafe™ System in Italy?
VVT Medical announced the first patients treated with its ScleroSafe™ System in Italy in May 2026.
What was the outcome of VVT Med's clinical data for ScleroSafe® in April 2026?
In April 2026, VVT Med announced positive clinical data for ScleroSafe® which was published in a peer-reviewed Indian Journal of Vascular and Endovascular Surgery.

Team · 12

Erez Tetro
CEO & Director
Dor Sneh
CFO & Corporate Secretary
Liron Tayeb
VP R&D
Pazit Waks
VP QA&RA
Orly Efraty
VP Global Marketing
Eyal Alon
VP Global Sales
Gidi Vitkon
COO
Gregory Gelman
R&D Engineer
Yair Aloni
Chairman of the Board of Directors
Doron Birger
Director
Sophie Galper-Komet
Director
Stephen Gledhill
Director

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 Patents

Tags

medical-devicescatheterstreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)